<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026844</url>
  </required_header>
  <id_info>
    <org_study_id>07-037</org_study_id>
    <secondary_id>OSI4251s</secondary_id>
    <nct_id>NCT01026844</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Erlotinib is a type of drug called a tyrosine kinase inhibitor (TKI). TKIs block a protein
      called epidermal growth factor receptor (EGFR). EGFR may control tumor growth and tumor cell
      survival. EGFR is found on the surface of many types of cancer cells, including non-small
      cell lung cancer (NSCLC). Erlotinib is approved by the Food and Drug Administration (FDA) for
      the treatment of NSCLC. Hydroxychloroquine (HCQ) is a drug approved by the FDA for treatment
      of malaria, rheumatoid arthritis, and several other diseases but is not currently thought of
      as a cancer treatment. Previous laboratory studies suggests that HCQ may have an anti-cancer
      effect by itself in some situations, particularly when EGFR TKI drugs have been useful in the
      past against the tumor. The two drugs together may be able to fight lung cancer in cases
      where erlotinib is no longer effective by itself. The purpose of this research study is to
      determine the highest dose of HCQ that can be given safely in combination with erlotinib. We
      will also begin to look at whether HCQ plus erlotinib helps treat cancer that have become
      resistant to TKI treatment after initially responding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The goal of this study is to find the highest dose of HCQ that can be given safely with
           erlotinib. Therefore, not all participants will receive the same dose of HCQ. Small
           groups of participants will be enrolled in steps in this trial. The first group will be
           given a certain dose of HCQ. If they have few or manageable side effects, the next small
           group of participants enrolled will receive a higher dose. This increase in doses will
           continue until the research doctors find the highest dose of HCQ that can be given
           without causing severe or unmanageable side effects.

        -  Both HCQ and erlotinib are pills that are taken orally. Treatment will be divided into
           time periods called cycles. Each treatment cycle is 28 days. The exception to this 28
           day cycle is when participants start taking the pills for the first time. Erlotinib is
           started first for 7 days and then HCQ is added. When the HCQ begins, the first cycle of
           28 days begins.

        -  There are several tests and procedures that will be performed at specific time periods
           during protocol treatment. These include: blood work, performance status assessment,
           questions about medical history and medications, tumor assessment with CT or MRI and,
           eye exams.

        -  Participants may continue to receive study treatment as long as they do not experience
           unacceptable side effects or disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow enrollment
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the Number and Type of Observed Dose Limiting Toxcities</measure>
    <time_frame>2 years</time_frame>
    <description>HCQ doses tested included 400mg, 600mg, 800mg, and 1000mg. Dose-limiting toxicities (DLTs) were defined as CTC of grade 2 or higher retinopathy or keratitis, or CTC of grade 3 or higher hematologic, skin, CNS, neuropathic, cardiac, respiratory, gastrointestinal, or renal AEs in the first cycle considered at least possibly related to HCQ. If a DLT was observed, an additional three patients were enrolled at that dose level. The maximum tolerated dose for HCQ in each arm would be defined as one dose level below that at which two or more of 6 patients experienced a DLT, or if no DLTs were observed, the highest tested dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the Pharmacokinetic (PK) Parameters of Hydroxychloroquine (HCQ) Plus Erlotinib.</measure>
    <time_frame>2 years</time_frame>
    <description>PK parameter tested was dose normalized minimum steady state concentration (Cmin SS) of HCQ in micromolar per gram. Note this outcome was only analyzed for the first 21 patients enrolled, 13 on erlotinib/HCQ and 8 on HCQ arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Number of Response Evaluation Criteria in Solid Tumors (RECIST) responses divided by number of patients treated. Per RECIST version 1.0 complete response (CR) is defined as disappearance of all target lesions; Partial Response (PR) is defined as &gt;=30% decrease in the sum of the longest diameter of target lesions. The objective tumor response rate is the CR + PR divided by the total number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR Amplification With Response to Treatment in Patients With Available Tumor Specimens.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Erlotinib plus hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroqine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Taken orally once a day</description>
    <arm_group_label>Erlotinib plus hydroxychloroquine</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
    <description>Taken orally once a day</description>
    <arm_group_label>Erlotinib plus hydroxychloroquine</arm_group_label>
    <arm_group_label>Hydroxychloroqine</arm_group_label>
    <other_name>HCQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of non-small cell lung cancer

          -  Stage IIIB with pleural effusion or Stage IV disease by the American Joint Committee
             on Cancer (AJCC) 6th edition staging criteria.

          -  At least 12 weeks of prior treatment with erlotinib, gefitinib, or another EGFR small
             molecule TKI agent.

          -  Age equal to or greater than 18 years

          -  Measurable disease, defined according to RECIST criteria

          -  Performance status of 0, 1 or 2

          -  At least 2 weeks since prior radiation treatment

          -  At least 2 weeks since any prior chemotherapy or targeted therapy

          -  Adequate organ function as outlined in the protocol

          -  Approval for HCQ treatment by an eye doctor, based on a screening eye exam. Examples
             of disqualifying baseline conditions include macular degeneration and other retinal
             disease.

          -  Willingness to comply with protocol procedures including the blood-sampling schedule
             for PK analyses and periodic eye examination

        Exclusion Criteria:

          -  Current use of hydroxychloroquine for any reason

          -  Known hypersensitivity to chloroquine, hydroxychloroquine, or any other closely
             related drug

          -  Known hypersensitivity to erlotinib, gefitinib, or any closely related drug

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency, as HCQ may cause hemolytic anemia
             in patients with G6PD deficiency

          -  Cataracts that would interfere with required funduscopic examinations, or severe
             baseline visual impairment including macular degeneration, retinopathy or visual field
             changes, or having only one functional eye. All patients must undergo a screening eye
             exam prior to enrollment

          -  Pregnancy or breastfeeding. Female subjects of childbearing age and male subjects must
             practice acceptable method of birth control

          -  Symptomatic CNS metastases or newly diagnosed CNS metastases that have not yet been
             definitively treated with radiation and/or surgery

          -  Prior radiation therapy inclusive of all identified target lesions

          -  Any evidence of clinically active interstitial lung disease

          -  Malignancies within the past 3 years except for adequately treated carcinoma of the
             cervix or basal or squamous cell carcinomas of the skin

          -  Although not an absolute exclusion criteria, caution should be exercised in patients
             with a diagnosis of porphyria or non-light sensitive psoriasis, as HCQ can
             significantly exacerbate both of those conditions

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the patient to participate in the study

          -  Use of any non-FDA approved or investigational agent within 2 weeks of enrolling onto
             the trial, or failure to recover from the side effects of any of these agents

          -  Penicillamine use for Wilson's disease or any other indication, as concomitant use
             with HCQ can increase toxicity to penicillamine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lecia Sequist, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachussets General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct;7(10):1602-8. doi: 10.1097/JTO.0b013e318262de4a.</citation>
    <PMID>22878749</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <results_first_submitted>November 25, 2012</results_first_submitted>
  <results_first_submitted_qc>June 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 31, 2013</results_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Lecia V. Sequist</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <keyword>tarceva</keyword>
  <keyword>hydroxychloroquine</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty-seven patients were enrolled between August 2007 and May 2010. They were all patients at Mass General Hospital Cancer Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib Plus HCQ (Hydroxychloroquine)</title>
          <description>Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)</description>
        </group>
        <group group_id="P2">
          <title>HCQ (Hydroxychloroquine)</title>
          <description>HCQ at escalating doses (400mg, 600mg, 800mg, and 1000mg QD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib Plus HCQ (Hydroxychloroquine)</title>
          <description>Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)</description>
        </group>
        <group group_id="B2">
          <title>HCQ (Hydroxychloroquine)</title>
          <description>HCQ at escalating doses (400mg, 600mg, 800mg, and 1000mg QD)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="27" upper_limit="73"/>
                    <measurement group_id="B2" value="61" lower_limit="48" upper_limit="76"/>
                    <measurement group_id="B3" value="64" lower_limit="27" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Describe the Number and Type of Observed Dose Limiting Toxcities</title>
        <description>HCQ doses tested included 400mg, 600mg, 800mg, and 1000mg. Dose-limiting toxicities (DLTs) were defined as CTC of grade 2 or higher retinopathy or keratitis, or CTC of grade 3 or higher hematologic, skin, CNS, neuropathic, cardiac, respiratory, gastrointestinal, or renal AEs in the first cycle considered at least possibly related to HCQ. If a DLT was observed, an additional three patients were enrolled at that dose level. The maximum tolerated dose for HCQ in each arm would be defined as one dose level below that at which two or more of 6 patients experienced a DLT, or if no DLTs were observed, the highest tested dose.</description>
        <time_frame>2 years</time_frame>
        <population>In October 2008, after enrollment of 18 patients (8 on arm A and 10 on arm B), the study was amended to limit enrollment to arm B only (HCQ plus erlotinib) given the increasing preclinical evidence supporting a role for combination therapy (but not HCQ monotherapy) and to help increase overall patient accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib Plus HCQ (Hydroxychloroquine)</title>
            <description>Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)</description>
          </group>
          <group group_id="O2">
            <title>HCQ (Hydroxychloroquine)</title>
            <description>HCQ at escalating doses (400mg, 600mg, 800mg, and 1000mg QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Describe the Number and Type of Observed Dose Limiting Toxcities</title>
          <description>HCQ doses tested included 400mg, 600mg, 800mg, and 1000mg. Dose-limiting toxicities (DLTs) were defined as CTC of grade 2 or higher retinopathy or keratitis, or CTC of grade 3 or higher hematologic, skin, CNS, neuropathic, cardiac, respiratory, gastrointestinal, or renal AEs in the first cycle considered at least possibly related to HCQ. If a DLT was observed, an additional three patients were enrolled at that dose level. The maximum tolerated dose for HCQ in each arm would be defined as one dose level below that at which two or more of 6 patients experienced a DLT, or if no DLTs were observed, the highest tested dose.</description>
          <population>In October 2008, after enrollment of 18 patients (8 on arm A and 10 on arm B), the study was amended to limit enrollment to arm B only (HCQ plus erlotinib) given the increasing preclinical evidence supporting a role for combination therapy (but not HCQ monotherapy) and to help increase overall patient accrual.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Pharmacokinetic (PK) Parameters of Hydroxychloroquine (HCQ) Plus Erlotinib.</title>
        <description>PK parameter tested was dose normalized minimum steady state concentration (Cmin SS) of HCQ in micromolar per gram. Note this outcome was only analyzed for the first 21 patients enrolled, 13 on erlotinib/HCQ and 8 on HCQ arm.</description>
        <time_frame>2 years</time_frame>
        <population>The patients participating in the randomized portion of the study were analyzed for PK parameters. When the HCQ alone arm of the study was closed, PK measurements were no longer performed</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib Plus HCQ (Hydroxychloroquine)</title>
            <description>Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)</description>
          </group>
          <group group_id="O2">
            <title>HCQ (Hydroxychloroquine)</title>
            <description>HCQ at escalating doses (400mg, 600mg, 800mg, and 1000mg QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Pharmacokinetic (PK) Parameters of Hydroxychloroquine (HCQ) Plus Erlotinib.</title>
          <description>PK parameter tested was dose normalized minimum steady state concentration (Cmin SS) of HCQ in micromolar per gram. Note this outcome was only analyzed for the first 21 patients enrolled, 13 on erlotinib/HCQ and 8 on HCQ arm.</description>
          <population>The patients participating in the randomized portion of the study were analyzed for PK parameters. When the HCQ alone arm of the study was closed, PK measurements were no longer performed</population>
          <units>micromolar per gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" spread="2.51"/>
                    <measurement group_id="O2" value="9.40" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response Rate</title>
        <description>Number of Response Evaluation Criteria in Solid Tumors (RECIST) responses divided by number of patients treated. Per RECIST version 1.0 complete response (CR) is defined as disappearance of all target lesions; Partial Response (PR) is defined as &gt;=30% decrease in the sum of the longest diameter of target lesions. The objective tumor response rate is the CR + PR divided by the total number of patients</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib Plus HCQ (Hydroxychloroquine)</title>
            <description>Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)</description>
          </group>
          <group group_id="O2">
            <title>HCQ (Hydroxychloroquine)</title>
            <description>HCQ at escalating doses (400mg, 600mg, 800mg, and 1000mg QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate</title>
          <description>Number of Response Evaluation Criteria in Solid Tumors (RECIST) responses divided by number of patients treated. Per RECIST version 1.0 complete response (CR) is defined as disappearance of all target lesions; Partial Response (PR) is defined as &gt;=30% decrease in the sum of the longest diameter of target lesions. The objective tumor response rate is the CR + PR divided by the total number of patients</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="1" upper_limit="25"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlate Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR Amplification With Response to Treatment in Patients With Available Tumor Specimens.</title>
        <time_frame>2 years</time_frame>
        <population>Because so few responses were observed, this exploratory outcome was not analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib Plus HCQ (Hydroxychloroquine)</title>
            <description>Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)</description>
          </group>
          <group group_id="O2">
            <title>HCQ (Hydroxychloroquine)</title>
            <description>HCQ at escalating doses (400mg, 600mg, 800mg, and 1000mg QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Correlate Epidermal Growth Factor Receptor (EGFR) Mutations and EGFR Amplification With Response to Treatment in Patients With Available Tumor Specimens.</title>
          <population>Because so few responses were observed, this exploratory outcome was not analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib Plus HCQ (Hydroxychloroquine)</title>
          <description>Erlotinib at 150mg QD and HCQ at escalating doses (400mg, 600mg, 800mg and 1000mg QD)</description>
        </group>
        <group group_id="E2">
          <title>HCQ (Hydroxychloroquine)</title>
          <description>HCQ at escalating doses (400mg, 600mg, 800mg, and 1000mg QD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nail changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of study leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lecia Sequist, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-4000</phone>
      <email>lvsequist@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

